News & Updates
Showing Pharmacy articles
Showing

Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.

Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.

Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
The use of chlorthalidone in the treatment of patients with hypertension does not appear to provide better protection against major cardiovascular outcome events or noncancer-related deaths when compared with hydrochlorothiazide, according to a study.

Investigational antisense oligonucleotide for chronic HBV infection shows positive results
Treatment with the antisense oligonucleotide bepirovirsen appears to lead to sustained loss of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA in up to 10 percent of patients with chronic HBV infection, according to the results of the phase IIb study B-Clear.

Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.

5α-reductase inhibitor treatment implicated in dementia
Men who are receiving treatment with 5α-reductase inhibitors (5-ARIs) are at increased risk of dementia in the immediate period after initiating treatment, a study has shown. Of note, both finasteride and dutasteride are associated with depression, but neither of them is linked to suicide.

Edoxaban prevents thromboembolism in children with cardiac disease
Edoxaban may be used as an alternative treatment for thromboembolism (TE) prevention in children with cardiac disease showing low rates of clinically relevant bleeding and TE, suggests a study. Some of its advantages include once-daily dosing and infrequent monitoring requirement.


